The International Society of Pharmacovigilance (ISoP) is supporting members throughout the world during the COVID-19 pandemic, say authors of an article published in *Drug Safety*.

New drugs such as remdesivir and repurposed drugs including hydroxychloroquine and lopinavir/ritonavir are being investigated for the treatment of COVID-19 infections, and various types of COVID-19 vaccines are underdevelopment. Suspected adverse drugs reactions (ADRs) to these drugs are being reported to Vigibase, the WHO global database of individual case safety reports (ICSRs) which is managed by the Uppsala Monitoring Centre in Sweden.

The ISoP risk communication special interest group (SIG) and the ISoP communications team have been discussing the role of ISoP in providing information about the COVID-19 pandemic, particularly with respect to the efficacy and safety of medicines and vaccines for the treatment and prevention of COVID-19. The ISoP executive committee (EC) has been in contact with pharmacovigilance colleagues in countries throughout the world and anticipates that support will particularly be necessary to manage challenges in lower-income countries with limited resources, such as knowledge sharing and providing insight into regulatory decisions and communication materials and social media campaigns.

The ISoP EC has made changes to the 2020 strategic plan and postponed conferences, meetings and the annual meeting until 2021. Key initiatives of ISoP during 2020 include: monitoring publications on drugs and vaccines used in the treatment or prevention of COVID-19; supporting regional pharmacovigilance organisations during the pandemic; conducting webinars in collaboration with *Drug Safety*; and \"encouraging ISoP chapters and SIGs to continue relevant work and share key outputs with other ISoP members\".
